Karen Wagner is a senior executive and entrepreneur with 25 years’ experience in the biopharmaceutical industry. Karen is Managing Partner at Ysios Capital and has a leading role in the investment team and the portfolio.

Prior to joining Ysios in 2008, she was a Global Alliance Director for F. Hoffmann-La Roche in Basel, Switzerland. She joined Roche from GLYCART, a biotech company in the antibody engineering space, which was acquired by Roche in 2005. Previously she was a Consultant with McKinsey & Company’s Global Healthcare Practice. She serves on the Boards of  Cytoki Pharma, Vivet Therapeutics, AELIX Therapeutics, Minoryx Therapeutics, Synendos and SparingVision and holds an observer seat at Xeltis. Formerly, she was Board Member at Xeltis, Cardoz, Kala Pharmaceuticals (NASDAQ:KALA), and Galecto (NASDQ:GLTO).

She holds a master’s degree in Molecular Biology and a PhD in Cell Biology.